EDSA: EB05 cuts 28-day ARDS mortality by 13% in Phase 3

Edesa Biotech (EDSA) reported positive Phase 3 results for paridiprubart (EB05) in ARDS, stating the study met primary and secondary endpoints with statistical significance.

Accepted by SEC EDGAR 10/28/2025 - 07:45 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Edesa Biotech (EDSA) reported positive Phase 3 results for paridiprubart (EB05) in ARDS, stating the study met primary and secondary endpoints with statistical significance. In the intention-to-treat population (n=104), 28-day mortality was 39% with paridiprubart plus standard of care versus 52% with placebo, an absolute survival improvement of 13% and a 25% relative risk reduction (p<0.001). A survival benefit persisted at 60 days: 46% vs 59%, a 13% absolute improvement and 22% relative risk reduction (p=0.003).

The company also reported fewer patients required invasive mechanical ventilation, with a 41% higher relative rate of clinical improvement at Day 28. In a safety population of more than 275 subjects across Phase 2/3, EB05 was generally well-tolerated. Patients were enrolled at 38 hospitals in the U.S., Canada and Colombia. The program is supported by the U.S. government’s “Just Breathe” study and Canada’s Strategic Innovation Fund. Enrollment was discontinued early for business reasons, and efficacy analyses used multivariate logistic regression with prespecified adjustments.

Positive

• Phase 3 success in ARDS: EB05 met primary and secondary endpoints with significant 28-day and 60-day mortality reductions.

Negative

• None.

Insights

Biopharma clinical outcomes analyst

Phase 3 met endpoints with mortality reduction; strong clinical signal.

Edesa Biotech reports that paridiprubart (EB05) met primary and secondary endpoints in ARDS with statistically significant mortality reductions at 28 and 60 days. The ITT analysis (n=104) shows 28-day mortality of 39% vs 52% (p<0.001) and 60-day mortality of 46% vs 59% (p=0.003), alongside a 41% higher relative rate of clinical improvement at Day 28.

Safety across >275 subjects was generally consistent with prior experience. The analysis applied multivariate logistic regression with adjustments for baseline and concomitant treatments, which can strengthen interpretability within the truncated enrollment context.

Further visibility may come from the U.S. “Just Breathe” study and program activities supported by Canada’s Strategic Innovation Fund. The durability of effect across 28 days and 60 days is notable; subsequent disclosures could clarify regulatory and development steps.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edesa Biotech (EDSA) announce about EB05?

The company reported positive Phase 3 results in ARDS, stating EB05 met primary and secondary endpoints with statistical significance.

How did EB05 affect 28-day mortality in the Phase 3 ARDS study for EDSA?

28-day mortality was 39% with EB05 plus standard of care vs 52% with placebo, a 13% absolute improvement (p<0.001).

What were the 60-day survival results for Edesa Biotech's EB05?

60-day mortality was 46% with EB05 vs 59% with placebo, a 13% absolute improvement and 22% relative risk reduction (p=0.003).

Did EB05 reduce the need for invasive mechanical ventilation (IMV)?

Yes. Subjects receiving EB05 plus standard of care showed a 41% higher relative rate of clinical improvement at Day 28.

How large was the safety population in Edesa Biotech’s EB05 program?

The safety population included more than 275 subjects across Phase 2 and Phase 3, and EB05 was generally well-tolerated.

Where was the EDSA Phase 3 ARDS study conducted?

Patients were enrolled at 38 hospitals across the U.S., Canada and Colombia.

Who supports Edesa Biotech’s EB05 development?

The program is part of the U.S. government’s “Just Breathe” study and receives funding from Canada’s Strategic Innovation Fund.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001540159 0001540159 2025-10-28 2025-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 28, 2025

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

British Columbia, Canada	001-37619	N/A
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

100 Spy Court, Markham, Ontario, Canada	L3R 5H6
(Address of Principal Executive Offices)	(Zip Code)

(289) 800-9600

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Shares		EDSA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 8, 2025, Edesa Biotech, Inc. (the “Company”) announced positive results from a Phase 3 study evaluating the Company’s drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (“ARDS”), a life-threatening form of respiratory failure.

The data from the Phase 3 study demonstrated that paridiprubart met primary and secondary endpoints with statistical significance. Paridiprubart led to a clinically significant reduction in mortality through 60 days, as well as a significant reduction in the proportion of patients requiring invasive mechanical ventilation (“IMV”).

Paridiprubart in the most conservative intention-to-treat (“ITT”) population met the primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. Patients treated with paridiprubart plus standard of care treatments (“SOC”) had a lower risk of death (39%) compared to those receiving placebo (52%), representing an absolute improvement in survival of 13% at 28 days with paridiprubart demonstrating a relative reduction in the risk of death of 25% compared to placebo (n=104; p<0.001). A durable survival benefit was also demonstrated at 60 days, with patients treated with paridiprubart plus SOC demonstrating a lower risk of death (46%) compared to those receiving placebo (59%), representing an absolute improvement in survival of 13% with a relative risk reduction of 22% for paridiprubart compared to placebo (n=104; p=0.003). In addition, subjects receiving paridiprubart + SOC demonstrated a 41% higher relative rate of clinical improvement, meaning patients no longer required IMV and/or organ support at Day 28.

The results from a safety population of more than 275 subjects, which included patients enrolled during the interim between the Phase 2 and Phase 3 study, demonstrated that EB05 was generally well-tolerated and consistent with the observed safety profile to date.

Paridiprubart is currently being evaluated in the U.S. government’s “Just Breathe” study investigating three novel threat-agnostic therapeutics in hospitalized adult patients with ARDS. The Company’s paridiprubart development program, including this Phase 3 study and manufacturing scale-up, also receives funding from the Government of Canada’s Strategic Innovation Fund.

Detailed Results

Patients were enrolled from 38 hospitals in the USA, Canada and Colombia. Participants were 18 years or older, receiving IMV with or without additional organ support at the time of hospitalization. They were randomly assigned (1:1) to SOC with paridiprubart (15mg/kg, maximum dose of 1400mg, n=56), or SOC with placebo (n=48). Efficacy outcomes were 28-day and 60-day mortality and proportion of patients with a decrease of ≥ 2 points in the WHO COVID-19 Severity Scale (WCSS) at 28-days. As previously disclosed, the Company opted to discontinue enrollment early for business reasons.

Patient demographics and baseline disease parameters were similar for the two groups with overall mean (SD) age: 52 (20-86) years, female (34%), severe ARDS (55%); moderate ARDS (38%); mild ARDS (5%), antivirals (10%), corticosteroids (44%), immunomodulators (10%), IMV only (36%), IMV with additional organ support (64%), acute kidney injury (26%), sepsis (20%), pneumonia (40%).

The following tables summarize the key results from the truncated Phase 3 study.

Mortality Rate at 28 Days and 60 Days

Multivariate Logistic Regression Derived Risk Differences, 95%CI*

Timepoint	Paridiprubart	Placebo	P-Value**
28-Day	0.39 (0.35, 0.44)	0.52 (0.47, 0.58)	<0.001
60-Day	0.46 (0.42, 0.50)	0.59 (0.55, 0.63)	0.003
Adjusted mortality risk estimate: variables included age, baseline WCSS, baseline antiviral use, baseline corticosteroid use, baseline immunomodulator use, concomitant antiviral use, concomitant corticosteroid use, concomitant immunomodulator use. Intent to treat (ITT) population; n=104. **P-value based on Wald test for parameter estimate.

Achievement of ≥2-Point Improvement in WCSS at 28 Days

Multivariate Logistic Regression Derived Risk Differences, 95%CI*

Paridiprubart	Placebo	P-Value**
0.38 (0.31, 0.45)	0.27 (0.21, 0.33)	0.032
Adjusted risk estimate: variables included age, baseline WCSS, baseline antiviral use, baseline corticosteroid use, baseline immunomodulator use, concomitant antiviral use, concomitant corticosteroid use, concomitant immunomodulator use. ITT population; n=104. **P-value based on Wald test for parameter estimate.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Edesa Biotech, Inc.
Date: October 28, 2025	By:	/s/ Peter J. Weiler
	Name:	Peter J. Weiler
	Title:	Chief Financial Officer